About this trial
A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity.
The goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.
Eligibility criteria
Qualifiers
Undergoing breast reduction surgery
Women older than age 18 and under age 75
Stable breast size for at least 1 year
Patient has evidence of severe breast hypertrophy that is documented by frontal and side profile photographs
Disqualifiers
History of chronic pain controlled with prescribed narcotics
English as non-primary language
No access to email or internet
Positive pre-surgery pregnancy test
Trial design
Treatments tested in this trial
- Pectoral II Nerve Block
- Post Operative Pain Relievers